Positron emission tomography in renal cell carcinoma: an imaging biomarker in development
AH Khandani, WK Rathmell - Seminars in nuclear medicine, 2012 - Elsevier
Positron emission tomography (PET) has revolutionized cancer imaging. The current
workhorse of molecular imaging, fluorodeoxyglucose (FDG) PET is used in the majority of
malignant tumors with a few exceptions. Renal cell carcinoma (RCC) is one of those
exceptions because of its variable uptake of FDG, although this variable uptake may actually
be an asset in predicting response to some targeted agents, as will be discussed later.
Beyond FDG, there is only scattered information in the literature on the use of PET in RCC …
workhorse of molecular imaging, fluorodeoxyglucose (FDG) PET is used in the majority of
malignant tumors with a few exceptions. Renal cell carcinoma (RCC) is one of those
exceptions because of its variable uptake of FDG, although this variable uptake may actually
be an asset in predicting response to some targeted agents, as will be discussed later.
Beyond FDG, there is only scattered information in the literature on the use of PET in RCC …